|
1
|
Eichhorst B, Dreyling M, Robak T,
Montserrat E and Hallek M; ESMO Guidelines Working Group. Chronic
lymphocytic leukemia: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 22(Suppl 6):
vi50–vi54. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brenner H, Gondos A and Pulte D: Trends in
long-term survival of patients with chronic lymphocytic leukemia
from the 1980s to the early 21st century. Blood. 111:4916–4921.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kiliańska ZM and Rogalińska M: Potential
new agents for chronic lymphocytic leukemia treatment. Anticancer
Agents Med Chem. 10:666–682. 2010.
|
|
4
|
Burger JA, Tsukada N, Burger M, Zvaifler
NJ, Dell’Aquila M and Kipps TJ: Blood-derived nurse-like cells
protect chronic lymphocytic leukemia B cells from spontaneous
apoptosis through stromal cell-derived factor-1. Blood.
96:2655–2663. 2000.PubMed/NCBI
|
|
5
|
Decker T, Hipp S, Ringshausen I, Bogner C,
Oelsner M, Schneller F and Peschel C: Rapamycin-induced G1 arrest
in cycling B-CLL cells is associated with reduced expression of
cyclin D3, cyclin E, cyclin A, and survivin. Blood. 101:278–285.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou Q and Liao JK: Pleiotropic effects of
statins. Basic research and clinical perspectives. Circ J.
74:818–826. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Roy M, Kung HJ and Ghosh PM: Statins and
prostate cancer: role of cholesterol inhibition vs. prevention of
small GTP-binding proteins. Am J Cancer Res. 1:542–561.
2011.PubMed/NCBI
|
|
8
|
Chapman-Shimshoni D, Yuklea M, Radnay J,
Shapiro H and Lishner M: Simvastatin induces apoptosis of B-CLL
cells by activation of mitochondrial caspase 9. Exp Hematol.
31:779–783. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pahan K: Lipid-lowering drugs. Cell Mol
Life Sci. 63:1165–1167. 2006. View Article : Google Scholar
|
|
10
|
Copajaa M, Venegasa D, Aránguiza P, et al:
Simvastatin induces apoptosis by a Rho-dependent mechanism in
cultured cardiac fibroblasts and myofibroblasts. Toxicol Appl
Pharmacol. 255:57–64. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wong WW, Dimitroulakos J, Minden MD and
Penn LZ: HMG-CoA reductase inhibitors and the malignant cell: the
statin family of drugs as triggers of tumor-specific apoptosis.
Leukemia. 16:508–519. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chan KK, Oza AM and Siu LL: The statins as
anticancer agents. Clin Cancer Res. 9:10–19. 2003.
|
|
13
|
Agarwal B, Halmos B, Feoktistov AS, et al:
Mechanism of lovastatin-induced apoptosis in intestinal epithelial
cells. Carcinogenesis. 23:521–528. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
van de Donk NW, Schotte D, Kamphuis MM,
van Marion AM, van Kessel B, Bloem AC and Lokhorst HM: Protein
geranylgeranylation is critical for the regulation of survival and
proliferation of lymphoma tumor cells. Clin Cancer Res.
9:5735–5748. 2003.PubMed/NCBI
|
|
15
|
Sleiffer S, van der Gaast A, Planting AS,
Stoter G and Verweij J: The potential of statins as part of
anti-cancer treatment. Eur J Cancer. 41:516–522. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhuang L, Kim J, Adam RM, Solomon KR and
Freeman MR: Cholesterol targeting alters lipid raft composition and
cell survival in prostate cancer cells and xenografts. J Clin
Invest. 115:959–968. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rai KR, Sawitsky A, Cronkite EP, Chanana
AD, Levy RN and Pasternack BS: Clinical staging of chronic
lymphocytic leukemia. Blood. 46:219–234. 1975.PubMed/NCBI
|
|
18
|
Kobylinska A, Bednarek J, Blonski JZ,
Hanausek M, Walaszek Z, Robak T and Kilianska ZM: In vitro
sensitivity of B-cell chronic lymphocytic leukemia to cladribine
and its combinations with mafosfamide and/or mitoxantrone. Oncol
Rep. 16:1389–1395. 2006.
|
|
19
|
Bellosillo B, Villamor N, Colomer D, Pons
G, Montserrat E and Gil J: In vitro evaluation of fludarabine in
combination with cyclophosphamide and/or mitoxantrone in B-cell
chronic lymphocytic leukemia. Blood. 94:2836–2843. 1998.PubMed/NCBI
|
|
20
|
Lowry OH, Rosebrough NJ, Farr AL and
Randall RJ: Protein measurement with the Folin phenol reagent. J
Biol Chem. 193:265–275. 1951.PubMed/NCBI
|
|
21
|
Towbin H, Staechlin T and Gordon J:
Electrophoretic transer of protein from polyacrylamide gels to
nitrocellulose sheets: procedure and some applications. Proc Natl
Acad Sci USA. 76:4350–4354. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kajstura M, Halicka HD, Pryjma J and
Darzynkiewicz Z: Discontinuous fragmentation of nuclear DNA during
apoptosis revealed by discrete ‘sub-G1’ peaks on DNA content
histograms. Cytometry A. 71:125–131. 2007.PubMed/NCBI
|
|
23
|
Kim J-S, Pirnia F, Choi YH, et al:
Lovastatin induces apoptosis in a primitive neuroectodermal tumor
cell line in association with RB down-regulation and loss of the G1
checkpoint. Oncogene. 19:6082–6090. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Podhorecka M, Halicka D, Klimek P, Kowal
M, Chocholska S and Dmoszyńska A: Simvastatin and purine analogs
have a synergic effect on apoptosis of chronic lymphocytic leukemia
cells. Ann Hematol. 89:1115–1124. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nijhawan D, Fang M, Traer E, Zhong Q, Gao
W, Du F and Wang X: Elimination of Mcl-1 is required for the
initiation of apoptosis following ultraviolet irradiation. Genes
Dev. 17:1475–1486. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Johnston JB, Paul JT, Neufeld NJ, et al:
Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic
leukemia. Leuk Lymphoma. 45:2017–2027. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kobylinska A, Blonski JZ, Hanausek M,
Walaszek Z, Robak T and Kilianska ZM: Determination of the in
vivo effects of cladribine alone and its combination with
cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and
Bcl-2 protein expression in B-CLL cells. Oncol Rep. 11:699–705.
2004.
|
|
28
|
Saxena A, Viswanathan S, Moshynska O,
Tandon P, Sankaran K and Sheridan DP: Mcl-1 and Bcl-2/Bax ratio are
associated with treatment response but not with Rai stage in B-cell
chronic lymphocytic leukemia. Am J Hematol. 75:22–33. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Muzio M, Apollonio B, Scielzo C, et al:
Constitutive activation of distinct BCR-signaling pathways in a
subset of CLL patients: a molecular signature of anergy. Blood.
112:188–195. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Grzybowska-Izydorczyk O, Cebula B, Robak T
and Smolewski P: Expression and prognostic significance of the
inhibitor of apoptosis protein (IAP) family and its antagonists in
chronic lymphocytic leukaemia. Eur J Cancer. 46:800–810. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Salman H, Bergman M, Djaldetti M and
Bessler H: Hydrophobic but not hydrophilic statins enhance
phagocytosis and decrease apoptosis of human peripheral blood cells
in vitro. Biomed Pharmacother. 62:41–45. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
McConkey DJ: Calcium-dependent,
interleukin 1-converting enzyme inhibitor-insensitive degradation
of lamin B1 and DNA fragmentation in isolated thymocyte nuclei. J
Biol Chem. 271:22398–22406. 1996.
|
|
33
|
Garnier P, Ying W and Swanson RA: Ischemic
preconditioning by caspase cleavage of poly(ADP-ribose)
polymerase-1. J Neurosci. 23:7967–7973. 2003.PubMed/NCBI
|
|
34
|
Vrhovac R, Delmer A, Tang R, Marie JP,
Zittoun R and Ajchenbaum-Cymbalista F: Prognostic significance of
the cell cycle inhibitor p27Kip1 in chronic B-cell
lymphocytic leukemia. Blood. 91:4694–4700. 1998.PubMed/NCBI
|
|
35
|
Eymin B, Sordet O, Droin N, et al:
Caspase-induced proteolysis of the cyclin-dependent kinase
inhibitor p27Kip1 mediates its anti-apoptotic activity.
Oncogene. 18:4839–4847. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zolnierczyk JD, Błoński JZ, Robak T,
Kiliańska ZM and Wesierska-Gadek J: Roscovitine triggers apoptosis
in B-cell chronic lymphocytic leukemia cells with similar
efficiency as combinations of conventional purine analogs with
cyclophosphamide. Ann NY Acad Sci. 1171:124–131. 2009. View Article : Google Scholar
|
|
37
|
Borner C: The Bcl-2 protein family:
sensors and checkpoints for life-or-death decisions. Mol Immunol.
39:615–647. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Skommer J, Wlodkowic D and Deptala A:
Larger than life: mitochondria and the Bcl-2 family. Leuk Res.
31:277–286. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Osmak M: Statin and cancer: current and
future prospects. Cancer Lett. 324:1–12. 2012. View Article : Google Scholar
|
